Jazz Pharmaceuticals (JAZZ) PT Lowered to $175 at Oppenheimer as Erwinaze Deal Terminated
Tweet Send to a Friend
Oppenheimer analyst Esther Rajavelu lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $175.00 (from $180.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
